Addition of Enoxaparin to Neoadjuvant Chemoradiation of Esophageal Cancer

NCT03254511 PHASE2 UNKNOWN

This is a randomized, single blind, multi-center, phase two clinical trial. Inclusion criteria are consist of non-metastatic esophageal cancer who are going to receive chemo-radiotherapy. Sample size is 100 people (50 people in each group). In the intervention group, patients are going to inject an enoxaparin (40 mg) daily concurrent by chemo-radiation. Therefore patients with esophageal cancer are going to assign randomly to control group (only chemo-radiotherapy) and intervention group (chemo-radiotherapy+enoxaparin) using 1:1 allocation. Four to 6 weeks after treatment, all patients undergo upper GI endoscopy and then esophagectomy. Endoscopic and pathological findings (after esophagectomy) are considered as clinical and pathological response, respectively.

Details

Lead sponsor	Mashhad University of Medical Sciences
Phase	PHASE2
Status	UNKNOWN
Enrolment	100
Start date	Fri Jul 22 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Dec 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Esophageal Neoplasms

Interventions

• Enoxaparin Sodium 40 MG/0.2 ML Subcutaneous Injectable
• Radiotherapy
• Chemotherapeutic Combinations

Countries

Iran